PepGen (PEPG) Projected to Post Quarterly Earnings on Wednesday

PepGen (NASDAQ:PEPGGet Free Report) is anticipated to announce its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

PepGen (NASDAQ:PEPGGet Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.13. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PepGen Price Performance

PEPG stock opened at $2.81 on Tuesday. The company has a market capitalization of $91.86 million, a PE ratio of -0.94 and a beta of 1.53. PepGen has a 12 month low of $1.16 and a 12 month high of $19.30. The firm’s 50-day moving average is $2.35 and its 200 day moving average is $5.61.

Analyst Ratings Changes

Several research analysts recently commented on PEPG shares. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of PepGen in a research report on Monday, February 24th. Finally, Wedbush cut their target price on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

Get Our Latest Stock Report on PepGen

PepGen Company Profile

(Get Free Report)

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

Featured Stories

Earnings History for PepGen (NASDAQ:PEPG)

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.